Tag Archives: results

Breakthrough Gene Therapy for Huntington’s Disease Demonstrates Promising Results in 2025

Posted on by
Reply

Huntington’s Disease: A Gradual Destruction of Brain Cells.

Science Photo Library/Alamy

This year marks a watershed moment in addressing Huntington’s disease, a rare yet impactful form of dementia. Researchers have achieved a groundbreaking milestone with an experimental gene therapy that effectively slows the advancement of this debilitating condition for the first time ever. This represents a significant breakthrough in the search for viable treatments.

According to Sarah Tabrizi from University College London, “This is a monumental step forward,” referencing the successes observed in late-stage trials earlier this year. “We now understand that Huntington’s disease is potentially treatable, presenting us with a tremendous opportunity.”

Huntington’s disease stems from a genetic mutation that causes the normally benign huntingtin protein to cluster into harmful aggregates within the brain. This accumulation leads to gradual deterioration of brain cells, hindering movement, cognitive function, and emotional well-being. Currently, no approved treatments halt the progression of symptoms, and care primarily focuses on supporting affected individuals.

The novel treatment, dubbed AMT-130, directly targets these abnormal proteins by delivering genetic instructions to brain cells, instructing them to produce molecules that inhibit protein formation.

In a recent investigation, Tabrizi and her team administered high doses of AMT-130 to 17 patients with Huntington’s disease. They evaluated changes in cognitive, motor, and daily functioning over a three-year period compared to a control group. Preliminary results released by the drug’s manufacturer, biotechnology firm uniQure, indicate a remarkable 75% average slowdown in symptom progression.

“Huntington’s disease treatment has faced numerous challenges in recent years,” stated Sarah O’Shea at Mount Sinai in New York, who was not involved in the study. “This accomplishment is significant, not just in delaying the disease’s progression but also because it arrives at a crucial time when hope is desperately needed.”

Nevertheless, this innovative treatment does come with its own set of challenges. Tabrizi explained that the 12- to 18-hour surgical procedure required to deliver the treatment deep within the brain is only accessible in a limited number of facilities in select countries, including the U.S. and U.K. Additionally, if approved, the treatment is likely to be prohibitively expensive. “Will it be accessible to all? Achieving that will be a challenge,” she remarked.

To navigate these hurdles, Tabrizi and her team are developing an alternative therapy that involves injecting the fluid around the spinal cord. “We’re currently conducting a Phase I study, and the first patient was treated in November 2024,” Tabrizi noted, with safety results expected by July 2026.

Meanwhile, uniQure’s executives revealed in September plans to submit AMT-130 for FDA approval in early 2026. However, the submission timeline is now uncertain, as the FDA has expressed concerns regarding the study plan and the control group, which consists of *non-treatment* patients drawn from a database.

The absence of a proper control group complicates the ability to discern the placebo effect on results. Still, given the surgical nature of the treatment, establishing such a group poses significant challenges.

“We firmly believe that AMT-130 holds substantial potential to benefit patients and are dedicated to collaborating with the FDA to expedite access to this treatment for families in need across the U.S.,” stated Matt Kapusta, CEO of uniQure.

Topics:

  • Dementia /
  • 2025 News Review

Source: www.newscientist.com

Tech Stocks Climb Following Strong Nvidia Results, Despite Concerns Over Chinese Competitors

Posted on by
Reply

Even though leaders in the AI chip industry have raised concerns about the emergence of Chinese competitors, tech stocks experienced an upswing on Thursday, buoyed by robust results from Nvidia.

The Stoxx Europe Tech Index increased by 0.8% on Thursday, leading to a 2.4% rise in Dutch semiconductor equipment manufacturer ASML. Meanwhile, in the US, tech-focused NASDAQ futures surged by 2%, alongside a 6% pre-market gain for Nvidia’s shares.

The uptick in tech and artificial intelligence stocks followed Nvidia’s report that surpassed Wall Street expectations, with quarterly revenues jumping 69% to $44 billion (£32.6 billion). The company also expressed optimism that business transactions in the Middle East could offset losses from China.

In April, former US President Donald Trump announced restrictions on AI chip exports to China, effectively cutting off a significant revenue stream, although Nvidia continues to sell H20 AI chips to Chinese firms.

Nvidia’s CEO Jensen Huang cautioned that Chinese competitors are capitalizing on the vacuum left by US trade barriers. “Chinese rivals have adapted,” Huang stated to Bloomberg TV. He noted that Huawei, which has been blacklisted by the US government, is “extremely formidable.” “Like everyone, their capabilities are multiplying each year,” Huang remarked. “The volume has also significantly increased.”

While US government policies aim to shield AI technology from Chinese influences, Huang indicated that domestic businesses are simply exploring alternative options. “The importance of the Chinese market should not be underestimated,” Huang noted. “It’s home to the largest population of AI researchers globally.”

Nvidia mentioned that it anticipates losing out on $8 billion in revenue for the second quarter due to Trump’s trade restrictions.

Tech investors felt positive after a recent judicial ruling that might challenge the president’s aggressive trade regime, as the US trade court opposed Trump’s severe tariff policies. Nonetheless, uncertainty looms since the White House has already appealed this decision from the International Trade Court based in New York.

In other news, shares of Tesla, another key player in AI technology, climbed by 2.6% after CEO Elon Musk confirmed his decision to step down from his role in the Trump administration.

Musk has been “at the helm of the Department of Government Efficiency (DOGE) since January, ruthlessly cutting expenditures across various public sectors and institutions. He announced in April his intention to resign following a decline in Tesla’s revenue and his failure to secure a Supreme Court position, which had consumed millions in support of Republican candidates.

Source: www.theguardian.com

AI Chatbot is Launched in UK Government to Assist Business Users – Results Are Mixed

Posted on by
Reply

Even though he knows a bit of Welsh and building regulations, he refrains from comparing Rishi Sunak to Keir Starmer or delving into the complexities of the UK corporation tax system. The UK government is introducing an artificial intelligence chatbot to assist businesses in navigating through a maze of 700,000 pages on the UK government website. Users can expect a range of outcomes from this new tool.

This experimental system will be initially tested with up to 15,000 business users and is expected to be widely available next year. However, users are cautioned about the limitations of AI tools like this one, which can sometimes provide false information with confidence. It is advised to cross-check the website link provided with each answer, which will be delivered within approximately 7 seconds. In a trial run in February, Paul Willmott, director of the Government’s Central Digital Data Agency, told reporters that there was a need for improvements to address hallucinations that may arise.

During a test run with reporters, it was observed that the chatbot, powered by OpenAI’s GPT-4o technology, displayed discrepancies in responses, including jumbled web links and short answers. The chatbot provided information on regulations for cannabis farmers but refrained from making predictions on cannabis legalization in the UK. It answered queries on building cladding regulations post-Grenfell Tower fire but steered clear of discussing the public inquiry findings on government failures.

On one occasion, the chatbot responded briefly in Welsh and avoided answering questions about the corporate tax system. However, it did offer information on incentives for installing solar panels. The chatbot’s training currently lacks coverage of all UK government documents, like ministerial speeches and press releases.

To ensure safe interactions, “guardrails” have been implemented to prevent the chatbot from providing illegal answers, divulging sensitive financial details, or taking political stances. Despite efforts to safeguard against hackers manipulating the chatbot, there remains a residual risk that cannot be completely eliminated.

Peter Kyle, Secretary of State for Science and Technology, expressed the government’s commitment to leveraging AI for enhancing public services in a secure manner. The aim is for the UK government to set an example in driving innovation and efficiency in public sector operations.

He emphasized the importance of streamlining government processes to save people time, noting that the average UK adult spends significant time dealing with public sector bureaucracy annually. Through initiatives like the UK Government Chat, the government is exploring innovative technologies to simplify interactions and improve efficiency.

Source: www.theguardian.com

Research shows new medication similar to Ozempic results in 13% reduction in body weight

Posted on by
Reply

Weight-loss medications like Ozempic and Wegovy have been under discussion for some time, but new research suggests there may be better alternatives. Enter Amicretin, a novel weight-loss treatment available in pill form rather than injection.

In the initial human trials of this new weight loss medication, the developer Novo Nordisk A/S (the company behind Ozempic) saw promising results: participants taking Amicretin lost an average of 13.1 percent of their body weight over a 12-week period.

So, how does this new weight loss pill function? Amicretin is a dual-acting drug that emulates the effects of two hormones crucial in weight loss: amylin and glucagon-like peptide-1 (GLP-1), which help curb hunger and regulate appetite.

Published in the journal Diabetology, the study compared average weight loss in three groups with BMIs between 25 and 39.9 who did not have diabetes.

By the end of the 12-week study, subjects taking two 50 mg tablets of Amicretin lost 13.1% of their body weight, compared to 10.4% in those taking one 50 mg tablet. In contrast, the placebo group only lost an average of 1.1% of their body weight throughout the study.

Compared to other weight loss drugs, a recent study in JAMA Internal Medicine found that patients taking another weight-loss drug, Maunjaro, lost 5.9% body fat in 3 months, while those on Ozempic saw a decrease of 3.6%.

“The difference from injectable treatments is significant,” states obesity expert Christopher Clemmensen. “The dual mode of action offers promise, making Amicretin a valuable advancement for Novo Nordisk.”

While weight-loss drugs show promise in combating obesity worldwide, further confirmation awaits larger trials on individuals with chronic conditions. Professor Navid Sattar emphasizes the importance of developing safe and accessible medications for the millions suffering from obesity.

Excitement surrounds this early-stage study of a novel oral weight-loss medication combination due to its rapid effects on body weight.

About our experts

Associate Professor Christopher Clemmensen leads the Clemmensen Group at the University of Copenhagen, studying biological weight regulation and developing obesity treatment strategies. His research appears in respected publications such as Natural Metabolism and Molecular Metabolism.

Read more:

Source: www.sciencefocus.com

Huge Search Yields Zero Results, Dealing Another Blow to Dark Matter

Posted on by
Reply

Source: www.newscientist.com

Rare genetic mutation results in stunning blue-skinned frog

Posted on by
Reply

The magnificent tree frog (Litoria splendida) is normally green, but this mutant is blue

J Barker/AWC

A rare blue frog found in the Kimberley region of Western Australia has stunned researchers who say the unusual colouring is probably due to a genetic mutation causing it to lose certain skin pigments.

As its name suggests, the magnificent tree frog (Litoria splendida) is already a spectacular animal, so when Jake Barker When he saw a bright blue specimen on a bench in a workshop at the Australian Wildlife Conservancy’s Charnley River-Artesian Range Wildlife Sanctuary in April, he was shocked.

The amphibians are normally a vibrant green, which is a common colour for tree frogs and is thought to camouflage them.

“I knew as soon as I saw it that it was rare,” says Barker. “It’s not often that you get to see a blue frog.” It has been seen a number of times since, but won’t be captured for research, he says.

“It’s far too pretty and far too unique and it would be a pity to take it away from its natural habitat,” says Barker. “We’ll leave it to live out its days and hopefully get to see it many more times in the future.”

Jodi Rowley At the Australian Museum in Sydney, the animal may be the “most beautiful, aberrant-coloured frog” that she has ever seen. “And I have seen tens of thousands of frogs.”

From the photos she has seen, Rowley says the frog is at least 2 to 3 years old. The species may live to be 20 years old, so the blue individual is likely to be around for a while unless caught by a predator.

She says the frogs’ skin colour is determined by the combination of three chemicals – melanophores, which provide blacks and browns; xanthophores, which provide yellow pigments; and iridophores, which reflect blue colours. Normally, the yellows and blues combine to make green, but it is thought the new blue frog has a mutation that means it is missing the yellow pigments and the blue dominates.

“Blue is probably a bit more obvious to predators,” says Rowley, “which is why we don’t see many blue frogs.”

Topics:

Source: www.newscientist.com

Playing Out Each UK Party’s First Years of Power in a Video Game Revealed Disastrous Results

Posted on by
Reply

circleWhether referred to as manifestos or contracts, the documents released by political parties before elections often lack substance despite their length. Filled with idealistic scenarios, vague proposals, and questionable cost estimates, it’s difficult to gauge the true impact each party’s implementation would have on the UK. To investigate this, I’ve been inputting party documents into the political strategy video game Democracy 4 to see the outcomes. The results are… well, you can see for yourself.

Democracy 4 allows players to simulate their political fantasies or nightmares and witness how their decisions influence their chances of re-election. Developed by Positech Games, the game models various democracies, including the UK, with their respective institutions, government policies, and tax rates based on publicly available data. The simulation features thousands of virtual voters, each with unique characteristics. For example, the majority of UK citizens identify as capitalists, but they may also be middle-income, affluent, or farmers, commuters, or self-employed.

Democracy 4 serves as an approximate representation of the British political landscape of 2024, offering insights into the potential outcomes of each major party’s agenda. By testing the policies of the Conservatives, Labour, and the Liberal Democrats, the game reveals who stands to benefit, who may be adversely affected, and whether any real progress can be achieved.




Simulated UK demographics. Photo: Positech Games

Keep in mind that Democracy 4 does not simulate Scotland and Wales separately, thus unable to capture the nuances of the SNP and Plaid Cymru’s plans. I have focused on the Conservatives, Labour, and the Liberal Democrats in my simulations. Each party assumes power with a slim 10% majority on July 5th, facing similar economic challenges. Can Labour bridge the funding gap across all sectors by boosting the UK economy? Will the Conservatives’ tax cuts stimulate business growth? And can the Liberal Democrats’ wealth tax and public service investments eliminate the national debt deficit?

Source: www.theguardian.com

Kristen Ager-Hansen’s approach to the Conservative Party results in £70,000 donation

Posted on by
Reply

While spying in Mallorca, Kristen Ager-Hansen received an email from the Conservative party headquarters. The email expressed gratitude for his interest in attending a private dinner with Suela Braverman, who was the Home Secretary at the time and oversaw Britain’s security services.

Ager Hansen, a Norwegian businessman, claimed to employ veterans of CIA, Mossad, and MI6 in his operations, catering to clients like eccentric billionaires with services ranging from surveillance to social engineering.

In July 2023, the Conservative Party received a £70,000 donation from nChain, a company where Ager Hansen was the CEO. Questions arose about the legitimacy of the donations and the scrutiny on the money influencing British politics.

Ager Hansen’s controversial past included orchestrating stings and covert operations, leading to his appointment as nChain’s CEO. He had confrontations with the law and creditors, showcasing his aggressive and unconventional tactics.

Despite the questionable donations and connections, Ager Hansen continued to make moves in high-profile circles, engaging with influential figures like Rishi Sunak and proposing lucrative projects to the Conservative Party.




Arger Hansen claims he orchestrated the sting to discredit lawyers litigating cases in the cryptocurrency industry. Photo: Rex/Shutterstock

“Data geek and intelligence officer”

Ager Hansen’s tumultuous career, marked by bankruptcies and legal issues, culminated in his role as nChain’s CEO. His aggressive and unorthodox approach to business and personal conflicts shaped his reputation as a street fighter.

His involvement in high-stakes operations with a team of experts from intelligence agencies painted a picture of a complex and controversial individual who thrived in chaotic environments.

Suela Braverman, then Home Secretary, at the 2023 Conservative Party Conference. Photo: Christopher Thomond/The Guardian

“Serious and inappropriate”

The Conservative Party’s association with Ager Hansen raised concerns about transparency and accountability, especially regarding the donations and the nature of his past operations. The party’s handling of the situation and his subsequent dismissal from nChain added to the controversy surrounding his actions.

Despite the fallout, Ager Hansen’s connections and proposed projects continued to spark intrigue and speculation, highlighting the complex web of relationships and influences within British politics.

Source: www.theguardian.com

James Cleverley warns that Britain’s enemies could utilize AI deepfakes to manipulate election results

Posted on by
Reply

The Home Secretary expressed concerns about criminals and “malicious actors” using AI-generated “deepfakes” to disrupt the general election.

James Cleverley, in anticipation of a meeting with social media leaders, highlighted the potential threats posed by rapid technological advancements to elections globally.

He cited examples of individuals working on behalf of countries like Russia and Iran creating numerous deepfakes (realistic fabricated images and videos) to influence democratic processes, including in the UK.

He emphasized the escalating use of deepfakes and AI-generated content to deceive and bewilder, stating that “the era of deepfakes has already begun.”

Concerned about the impact on democracy, he stressed the importance of implementing regulations, transparency, and user safeguards in the digital landscape.

The Home Secretary plans to propose collaborative efforts with tech giants like Google, Meta, Apple, and YouTube to safeguard democracy.


An estimated 2 billion people will participate in national elections worldwide in 2024, including in the UK, US, India, and other countries.

Incidents of deepfake audio imitations of politicians like Keir Starmer and Sadiq Khan, as well as misleading videos like the fake BBC News report on Rishi Sunak, have raised concerns.

In response, major tech companies have agreed to adopt precautions to prevent the misuse of AI tools for electoral interference.

Executives from various tech firms gathered at a conference to establish a framework for addressing deceptive AI-generated deepfakes that impact voters. Elon Musk’s Company X is among the signatories.

Mr. Clegg, Meta’s global president, emphasized the need for collective action to address the challenges posed by emerging technologies like deepfakes.

Source: www.theguardian.com

Google Ceases Notification of Publishers Regarding Removal of ‘Right to be Forgotten’ from Search Results

Posted on by
Reply

Google will inform publishers quietly that it has removed websites from search results under Europe’s “right to be forgotten” rules, following a Swedish court ruling that the search engine applies globally. Stopped.

Previously, when an individual requested that records about them be deleted under EU data protection law, Google would notify the publisher of the original article.

Media companies, including the Guardian, are largely exempt from regulation, but links to journalistic content can be removed from databases such as search engines.

Currently, Google only notifies publishers that a URL has been removed, without providing details about what or why.

As a result, journalists are unable to identify situations in which the right to be forgotten is being misused to obscure legitimate reporting about serial offenders, hampering their ability to challenge the most serious rights violations.

A Google spokesperson said: “We have introduced a new approach to notifications following a decision by the Swedish Data Protection Authority. It came into force.”

“Although we did not agree with this decision at the time, it is binding and supports EU-wide regulatory guidance. We have therefore made strong efforts to comply with it. Ta.”

One of the changes introduced by the GDPR in 2016 was to ensure that EU national court decisions on data protection set precedent across the bloc.

A Swedish court ruled in December that notifying webmasters that search engines have removed links to their content is itself a violation of the privacy of people who have requested the right to be forgotten.

“Thus, the Administrative Court found that once Google granted the deletion of search results, the interests of individuals in privacy and effective protection of personal data generally outweighed Google’s interests. [sic] Send a message to the webmaster, concludes. according to International Association of Privacy Professionals.

Upheld a 50 million Swedish kronor (£3.8 million) fine against search engines for failing to remove URLs they were asked to remove from their lists.

Skip past newsletter promotions

Within weeks of the first judgment in May 2014, which ruled that the right to be forgotten applied to Google, six Guardian articles were removed from the European version of the search engine.

Three of the charges related to now-retired Scottish Premier League referee Dougie McDonald, who was found to have lied about his reasons for awarding penalties in a football match in 2010. . Others included his 2002 article about a lawyer facing a fraud trial and his 2011 article about a French office worker who makes his art Post-It Notes.

Over the next five years, the search engine received about 1 million unique forgotten requests, and even though more than half were rejected, it still removed about 1.5 million unique URLs.

Source: www.theguardian.com

Lyft CEO takes responsibility for typo in financial results that led to 60% rise in stock price

Posted on by
Reply

Lyft performed well in the fourth quarter, exceeding profit expectations due to increased rides to stadiums and airports and significant cost savings.

However, the company’s stock price initially rose over 60% in after-hours trading, but most of those gains were erased after Lyft’s chief financial officer corrected a major error in its earnings report. The company had initially predicted growth of 500 basis points (5%) in 2024, but later announced that the actual growth rate was lower at 50 basis points (0.5%). In 2023, the stock price had risen by about 36%.

Lyft CEO David Risher acknowledged the mistake, saying in an interview the following day: bloomberg“Bad. This was a terrible error, but there was one zero.”

Lyft reported that stadium attendance increased over 35% from 2022, driven primarily by popular tours and sporting events. The company also highlighted improvements to airport transportation as contributing to its growth.

Under new leadership, Lyft implemented an aggressive restructuring plan last year, including staff cuts and the removal of management to pursue profitability. The company laid off 1,200 employees in April and reduced overall costs by 12%.

“We’re going to put more money into the bottom line because we can scale even further and keep costs flat,” Risher said.

Lyft also announced a new policy to pay drivers the difference if their income, after outside fees, is less than 70% of what a passenger pays. In addition, Lyft and Uber agreed to pay $328 million to a New York rideshare driver accused of withholding pay and benefits.

There are growing concerns about safety, job security, and the general fear of artificial intelligence with regard to self-driving cars. Lyft is addressing this by partnering with Motional to provide more than 100,000 self-driving rides across the United States.

Revenue for the quarter ended Dec. 31 was $1.22 billion, in line with analyst expectations. The company expects earnings before interest, taxes, depreciation, and amortization to be between $50 million and $55 million for the quarter, exceeding expectations of $46.3 million. Lyft’s fourth-quarter adjusted core profit was $66.6 million, also beating expectations of $56.2 million.

Source: www.theguardian.com

New Hope for Diabetes Treatment: Repurposed Medicines Present Promising Results

Posted on by
Reply

A recent study led by Indiana University and the University of Chicago Medicine suggests that a drug called alpha-difluoromethylornithine (DFMO) could revolutionize the treatment of type 1 diabetes. Based on a decade of research, DFMO has demonstrated the potential to reduce insulin dependence, and larger clinical trials are currently underway to evaluate DFMO’s impact on beta cell preservation and disease amelioration. Tested.

A recent study led by Indiana University School of Medicine in collaboration with the University of Chicago School of Medicine shows exciting future possibilities for the management of type 1 diabetes and its potential reduction. insulin dependence. The researchers’ findings are cell report medicine, They suggest that repurposing the drug alpha-difluoromethylornithine (DFMO) could open the door to innovative treatments in the future.

Type 1 diabetes is a chronic disease in which the body’s immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood sugar levels and currently requires lifelong insulin treatment to keep patients alive. Is required. Many people living with type 1 diabetes find current treatments, such as daily insulin injections and frequent blood sugar monitoring, inconvenient and difficult to manage.

A 10-year research journey

These latest translation results represent more than a decade of research. Raghu Mirmila, M.D., Ph.D., co-corresponding author of the study, said in 2010 that while running his lab at IU School of Medicine, his team was able to develop beta It was discovered for the first time that cells can be protected from infection. Environmental factors suggest that type 1 diabetes may be preserved. The team then validated these findings in mice.

From 2015 to 2019, Linda DiMeglio, MD, MPH, Edwin Letzter Professor of Pediatrics at IU School of Medicine, Pediatric Endocrinologist and Division Director at Riley Children’s Health, provided guidance to people with newly diagnosed type 1 diabetes. He led a clinical trial to confirm the safety of DFMO. They also suggested that it may stabilize insulin levels by protecting beta cells. The trial was funded by the Juvenile Diabetes Research Foundation (JDRF) and used the drug provided by Panvera Therapeutics.

Dr. Emily K. Sims. Credit: Chapital Photography, provided by Emily K. Sims

“After several years of bench-to-bedside research, Drs. [Sarah] “We are pleased to finally share the promising results from the Tercy mouse model, a pilot study in humans,” said DiMeglio, senior author of the study. “Having established the preliminary safety of DFMO in patients with type 1 diabetes, we are excited to collaborate to further explore its potential benefits in a larger clinical trial.”

Regulatory benefits of DFMO and new formulations

Since 1990, DFMO has been approved by the FDA as a high-dose injectable to treat African sleeping sickness, and in 2020 received breakthrough therapy designation as a post-remission neuroblastoma maintenance therapy. Ta. This prior regulatory approval could streamline adoption as a treatment for type 1 diabetes and shorten the approval process from decades to just a few years.

“Using the new formulation of DFMO as a pill allows patients to take it by mouth rather than needing regular injections, and it has a very favorable side effect profile,” said Dr. said one Milmira. Chicago Medicine. “We are very happy to be able to say that we have developed a drug that works differently than other treatments for this disease.”

Current and future clinical research

Researchers have already begun the next steps to investigate the potential of DFMO. The study’s lead author and co-corresponding author, Emily K. Sims, M.D., associate professor of pediatrics at IU School of Medicine and pediatric endocrinologist at Riley Children’s Health, recently studied the effects of infectious diseases in more detail. To define it, we have begun a large-scale clinical study involving six institutions. His DFMO treatment to preserve beta cell function in type 1 diabetes. This new research was also funded by JDRF and supported by Panbela Therapeutics.

Sims, who is also a physician and scientist at the IU School of Medicine’s Herman B. Wells Pediatric Research Center and Center for Diabetes and Metabolic Diseases, hopes that DFMO, perhaps as part of a combination therapy, will not only help patients; There is. People who have recently been diagnosed with type 1 diabetes but are at risk of developing the condition may also be tested.

“As we embark on this new multicenter clinical trial to further investigate the efficacy of DFMO, we are confident that the encouraging results obtained to date will allow us to modify the underlying disease process of type 1 diabetes. ”Sims said. “We invite even more participants to this pioneering study. With their help, the knowledge we gain today has the potential to shape a brighter future for people affected by type 1 diabetes. Masu.”

Reference: “Inhibition of polyamine biosynthesis preserves beta cell function in type 1 diabetes” Emily K. Sims, Abhishek Kulkarni, Audrey Hull, Stephanie E. Werner, Suzanne Cabrera, Lucy D. Mastrandrea, Batur Hammoud, Soumyadeep Sarkar, Ernesto S. Nakayas, Teresa L. Mastracci, Susan M. Perkins, Ouyang Fangqian, Bobbie Jo Webb Robertson, Jacob R. Enriquez, Sarah A. Turcy, Carmela Evans. · Molina, S. Alice Long, Lori Blanchfield, Eugene W. Garner, Raghavendra G. Mirmila and Linda A. Dimeglio, November 1, 2023; cell report medicine.
DOI: 10.1016/j.xcrm.2023.101261

People who want to know more about New clinical trials can be accessed on the research website.

Source: scitechdaily.com

Getaround’s Third Quarter Results Encourage Investors, but the Company Still Faces Challenges

Posted on by
Reply

peer-to-peer car sharing company Moving filed its first earnings report since going public a year ago Via SPAC combination. The company’s third-quarter earnings report details that while revenue is growing rapidly, it still doesn’t generate enough sales to cover expenses.

Getaround reported gross bookings of $69 million in the third quarter, resulting in revenue of $23.8 million in the period, up from $16.7 million in the year-ago period. In the first nine months of 2023, Getaround’s revenue reached his $54 million.

But while Getaround’s reported 42% year-over-year revenue growth in the third quarter has been well-received by investors, who have sent the stock up 75% in after-hours trading at the time of writing, the company is not. Still out of the forest.

Getaround’s operating expenses in the third quarter were worth $42.9 million, compared to the equivalent of $128 million for the first three quarters of this year, both numbers significantly higher than its gross profit for both periods. Still, Getaround has made some progress on the profitability front. In the third quarter, the company had a net GAAP loss of $27.3 million, an improvement of 16% from the third quarter of 2022 report. Using a more generous profit calculation, Get Around remained unprofitable in the latest quarter, with his adjusted EBITDA reported at -$11.3 million. Over the three-month period, it improved by 43% year-over-year.

Getaround is targeting gross bookings in the range of $200 million to $205 million for the full year of 2023. The company did not disclose revenue targets for this year, but third-quarter revenue reflects an annual run rate of more than $95 million. Getaround expects its 2023 adjusted EBITDA loss to be in the range of $68 million to $70 million.

Getaround ended the third quarter with $22.1 million in cash and cash equivalents. This number is a significant departure from the $64.3 million reported in cash and equivalents at the end of the third quarter of 2022. The company got some good news in the form of a $3 million infusion from Madrick Capital. Madrick Capital has an existing $15 million note with the company, which was expanded to provide a little more headroom for the getaround.

Getaround stock closed regular trading at about $0.17 on Thursday, ahead of the release of third-quarter data.

Rebuilding

Getaround is working to clean up its cost base, including reducing the company’s workforce. 10% of staff In February, the company announced that it would cut costs by $25 million to $30 million a year to achieve sustainability. The layoffs came a day after Getaround was declared a state of emergency. Delisting Notice from the New York Stock Exchange This is because the stock price was trading too low.

Now that the stock price has risen significantly following the earnings report, GetAround is still worth less than $1 per share, meaning it is still at risk of being delisted.Several SPAC combinations were executed reverse stock split This is probably why earnings per share have remained in the 100 yen range.

Getaround has also received other delisting notices for failing to timely file annual and quarterly reports. The company has not filed its 2022 annual report and just filed its third quarter earnings report. Getaround has not yet filed its first and second quarter results. The company says it will need more time to complete the audit and has now completed it.

Getaround CEO Sam Zaid told TechCrunch: Mr. Zaid would not comment on whether GetAround would seek a reverse stock split to boost its stock price.

car sharing companies too Acquires assets of startup HyreCar This will increase Getaround’s operating costs in the short term. Getaround hopes the scale provided by the acquisition will help accelerate its path to profitability.

This article has been updated with information from Getaround’s CEO.

Source: techcrunch.com